Page Heading Goes Here
Your content goes here. Edit or remove this text inline or in the module Content settings. You can also style every aspect of this content in the module Design settings and even apply custom CSS to this text in the module Advanced settings.
Page Heading Goes Here
Your content goes here. Edit or remove this text inline or in the module Content settings. You can also style every aspect of this content in the module Design settings and even apply custom CSS to this text in the module Advanced settings.
Heading Here
Your content goes here. Edit or remove this text inline or in the module Content settings. You can also style every aspect of this content in the module Design settings and even apply custom CSS to this text in the module Advanced settings.
Heading Here
Your content goes here. Edit or remove this text inline or in the module Content settings. You can also style every aspect of this content in the module Design settings and even apply custom CSS to this text in the module Advanced settings.
Heading Here
Your content goes here. Edit or remove this text inline or in the module Content settings. You can also style every aspect of this content in the module Design settings and even apply custom CSS to this text in the module Advanced settings.
Heading Here
Your content goes here. Edit or remove this text inline or in the module Content settings. You can also style every aspect of this content in the module Design settings and even apply custom CSS to this text in the module Advanced settings.
Heading Here
Your content goes here. Edit or remove this text inline or in the module Content settings. You can also style every aspect of this content in the module Design settings and even apply custom CSS to this text in the module Advanced settings.
Your Title Goes Here
Your content goes here. Edit or remove this text inline or in the module Content settings. You can also style every aspect of this content in the module Design settings and even apply custom CSS to this text in the module Advanced settings.
Your Title Goes Here
Your content goes here. Edit or remove this text inline or in the module Content settings. You can also style every aspect of this content in the module Design settings and even apply custom CSS to this text in the module Advanced settings.
Your Title Goes Here
Your content goes here. Edit or remove this text inline or in the module Content settings. You can also style every aspect of this content in the module Design settings and even apply custom CSS to this text in the module Advanced settings.
Your Title Goes Here
Your content goes here. Edit or remove this text inline or in the module Content settings. You can also style every aspect of this content in the module Design settings and even apply custom CSS to this text in the module Advanced settings.
BRF receives donation from Tencent of 20,000 KN95 respirator masks
BRF receives donation from Tencent of 20,000 KN95 respirator masks for distribution to healthcare settings in Northwest Louisiana BRF (formerly the Biomedical Research Foundation) has received a donation of 20,000 KN95 respirator masks from Tencent, a leading...
April 2020 Quarterly Report Now Available
For BRF's April 2020 Quarterly Report, click here.
BRF announces new chairman, board members
BRF is pleased to announce Lennis S. Elston, CPA as the new chairman of its Board of Directors. Elston has been a BRF board member for over five years and most recently served as vice chairman during 2019. She began her tenure as chairman in January 2020. Elston has...
BRF awarded Carolyn W. and Charles T. Beaird Family Foundation grant for Biotechnology Magnet Academy
BRF was recently awarded a grant from the Carolyn W. and Charles T. Beaird Family Foundation to purchase computers for Southwood High School students taking part in the Biotechnology Magnet Academy. It will also partially fund a College Navigator who helps Biotech...
EAP portfolio company’s $11 million grant advances drug to treat addictions
BRF Entrepreneurial Accelerator Program (EAP) portfolio company Embera NeuroTherapeutics has announced completion of its Series B financing that, combined with two grant awards, will fund initial EMB-001 Phase 2 clinical studies. A clinical stage pharmaceutical...